The efficacy and tolerance of high dose intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS was studied. Foscarnet in a dose of 2400 (Br3 Ophthalmol 1994; 78: 120-124) 
the vitreous of 11 patients (15 eyes). Five patients had active retinitis (eight eyes, 53.3%), and received a 3 week induction therapy of six injections as the first step. Six patients had initial inactive retinitis (seven eyes, 46.7%), and received only maintenance therapy which consisted of a weekly injection. The main indications for intravitreal therapy were: myelosuppression, kidney toxicity, catheter related sepsis, or refusal of intravenous therapy. The patients were foliowed for a mean period of 16 weeks (range weeks) and received a total of 304 injections. Vitreous foscarnet levels were measured by high performance liquid chromatography. After a 3 week course of induction therapy, complete resolution of the active retinitis was seen in 62-5% (5/8 cases), while 37*5% (3/8 cases) had partial resolution. No cases failed to respond or progress. The rate of relapse on maintenance therapy was 33% (five of 15 eyes) by 20 weeks, and two ofthese eyes did not respond to reinduction and progressed in involvement of the macula or optic nerve. Neither important local complications nor intraocular drug toxicity were observed. Vitreous foscarnet levels in two different patients were 8% ,mol/l and 749 umol/l at 223/4 hours and 421/2 hours after the injection. Intravitreal foscarnet appears to be a safe, effective, and useful alternative in patients with intolerance to intravenous antiviral therapy. (Br3 Ophthalmol 1994; 78: 120-124) Cytomegalovirus (CMV) retinitis is the most common opportunistic ocular infection in patients with AIDS. It Table 2 summarises the efficacy of the treatment. tenance intravenous treatment, and (iii) it Eleven patients (15 eyes) were studied and improves patient quality of life. An alternative to followed between 8 to 28 weeks (mean 16 weeks). multiple repeated intravitreal injections is the Six were homosexual men, two were male surgical implantation of an intravitreal device, injecting drug users, and three were hetero-which delivers ganciclovir intraocularly over sexual partners of seropositive subjects. Mean approximately 4 to 5 months. This implant has age was 36-6 years (range 29 to 44 years). demonstrated resolution of the CMV retinitis in Diagnosis of AIDS preceded the diagnosis of all cases in a long term clinical study,28 but witha CMV retinitis by a mean of 11-2 months (range high rate of complications, such as intraoperative 4 to 24 months). In the last follow up we found vitreous haemorrhage and suprachoroidal that seven of the 11 patients had died from implantation of the device. opportunistic infections.
Since foscarnet (trisodium phosphonoformate Cytomegalovirus retinitis was unilateral in hexahydrate) and ganciclovir are virostatic seven patients (63 6%) and bilateral in four agents, they must be administered continuously patients (36-4%). At recruitment, retinitis for life so as to avoid the progression of CMV affected only zone 1 in seven out of the 15 eyes, infection. Compared with ganciclovir, foscarnet zone 2 in two eyes, zone 3 in two eyes, both has the advantage of in vitro activity against both zones 2 and 3 in two eyes, and both zones 1 and 2 HIV and CMV. The drug has been shown to be in two eyes. A total of 304 injections were given. effective in ganciclovir resistant CMV retinitis.29 Bilateral injections were given when needed. When compared with intravenous administra-
The main indications for intravitreal therapy tion, intravitreal foscarnet has the advantage of were: myelosuppression (27 2%) (3/11), myelo-lacking renal toxicity which occurs in as many as suppression plus kidney toxicity (9%) (1/1 1), 46% of patients during systemic treatment.30 kidney toxicity alone (27-2%) (3/11), refusal of Encouraged by our initial results with low intravenous therapy (27-2%) (3/11) , and catheter dose intravitreal foscarnet,20 we have treated a related sepsis (9%) (1/1 1) . None of the patients series of 11 patients with multiple high dose with unilateral retinitis had developed CMV intravitreal injections. Because of the virostatic retinitis in the other eye at the last follow up. nature of foscarnet, all patients remained on Active retinitis showed no progression in all eyes maintenance therapy. CMV retinitis showed no 3 weeks after the beginning of intravitreal treat-progression in all eyes 3 weeks after induction therapy began. Resolution of exudative borders occurred within 5 to 6 weeks, and a complete area of atrophic retina could be seen as late as 8 to 10 weeks after the onset of the treatment. Despite successful induction and maintenance therapy, we have found evidence of relapse in five out of 15 eyes while on maintenance therapy (33-3% at 20 weeks). All relapses presented as an insidious active front at the margin of the scarred lesion ('smouldering'), without the appearance of new 'brushfire' lesions. Three responded to a second course of induction therapy.
Considered as a whole, these results showed clinical efficacy of intravitreal foscarnet similar to anti-CMV therapies previously reported, but with a lower relapse rate than those previously reported with intravitreal ganciclovir (33% to 45% at 8 to 12 weeks of maintenance therapy). 7919 24 This difference may be attributed to the proved development of resistance in patients treated with ganciclovir,3' which has not been reported with foscarnet. With intravenous foscarnet, a better response to the treatment seemed to be observed when zidovudine was added.'0 In this study the percentage of patients who responded to intravitreal foscarnet therapy with a complete resolution was higher in the group treated with zidovudine than in the group treated with foscarnet alone (without zidovudine).
Our experience has demonstrated that multiple intravitreal injections are well tolerated. Good intraocular tolerance is shown by the visual acuity remaining at 20/30 or more in seven eyes throughout the follow up period. The absence of retinal detachments in the present study shows a substantially lower incidence of this complication than in other clinical studies using intravitreal ganciclovir injections24 or an intravitreal device.28 Although retinal detachments have been attributed to microbreaks located in the porous junction of normal and atrophic retina, vitreous anomalies induced by ganciclovir (pH 10-14) may be a contributing factor. 24 The pH of foscarnet (7 4) which is closer to the physiological value could be an added advantage. Previous series using intravitreal therapy have reported an incidence of endophthalmitis of 0-4% tp 0-6%.17 1" The lack of intraocular infections in our series, consistent with that previously reported,24 could be attributed to the use of povidone iodine eyedrops before the injection. Although the dose used in this series is twice the amount used in a previous study, the intravitreal levels of foscarnet found (749 [tmol/l at 421/2 hours after injection of 2400 ,ug) are proportional to those previously described. Since these data were from different patients, no pharmacokinetic curve could be produced.
In 
